PMID- 31159608
OWN - NLM
STAT- MEDLINE
DCOM- 20190704
LR  - 20190704
IS  - 1751-2441 (Electronic)
IS  - 1751-2433 (Linking)
VI  - 12
IP  - 7
DP  - 2019 Jul
TI  - Changing the treatment paradigm for Parkinson's disease psychosis with 
      pimavanserin.
PG  - 681-691
LID - 10.1080/17512433.2019.1623669 [doi]
AB  - Introduction: Parkinson's disease psychosis (PDP) may affect up to 60% of 
      patients with Parkinson's disease over the course of their disease, and is 
      associated with poor prognosis, including increased risks of mortality and 
      nursing home placement. PDP treatments have been limited to off-label use of 
      atypical antipsychotics, most of which pose risks of worsened motor symptoms and 
      other potential adverse events (AEs) due to their dopamine receptor blockade and 
      additional off-target receptor affinities. Pimavanserin is a highly selective 
      5-HT(2A) inverse agonist and poses no known risks for worsening of parkinsonism 
      or other off-target receptor AEs. Pimavanserin is the first and only medication 
      approved for PDP treatment. Areas covered: This review covers estimated 
      prevalence, clinical characteristics, diagnostic criteria, and risk factors for 
      PDP; the hypothetical progression of PDP; management of PDP including use of 
      antipsychotics; pharmacology and clinical trial data on pimavanserin; and expert 
      opinion on PDP treatment. The NLM/PubMed database was searched for papers using 
      the search terms of "PDP" AND "treatment" AND "pimavanserin" for the last 10 
      years. Expert opinion: The recent insights into PDP pathophysiology and approval 
      of the only medication specifically to treat PDP are key advances that should 
      improve the recognition, diagnosis, and management of PDP.
FAU - Lyons, Kelly E
AU  - Lyons KE
AD  - a Department of Neurology , University of Kansas Medical Center , Kansas City , 
      KS , USA.
FAU - Pahwa, Rajesh
AU  - Pahwa R
AD  - a Department of Neurology , University of Kansas Medical Center , Kansas City , 
      KS , USA.
FAU - Hermanowicz, Neal
AU  - Hermanowicz N
AD  - b Department of Neurology , University of California Irvine , Irvine , CA , USA.
FAU - Davis, Thomas
AU  - Davis T
AD  - c Department of Neurology , Vanderbilt University Medical Center , Nashville , TN 
      , USA.
FAU - Pagan, Fernando
AU  - Pagan F
AD  - d Department of Neurology , Georgetown University Medical Center , Washington , 
      DC , USA.
FAU - Isaacson, Stuart
AU  - Isaacson S
AD  - e Parkinson's Disease and Movement Disorders Center of Boca Raton , Boca Raton , 
      FL , USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190613
PL  - England
TA  - Expert Rev Clin Pharmacol
JT  - Expert review of clinical pharmacology
JID - 101278296
RN  - 0 (Antiparkinson Agents)
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Piperidines)
RN  - 0 (Serotonin 5-HT2 Receptor Agonists)
RN  - 8W8T17847W (Urea)
RN  - JZ963P0DIK (pimavanserin)
SB  - IM
MH  - Antiparkinson Agents/pharmacology/therapeutic use
MH  - Antipsychotic Agents/pharmacology/therapeutic use
MH  - Disease Progression
MH  - Humans
MH  - Parkinson Disease/*drug therapy/physiopathology/psychology
MH  - Piperidines/pharmacology/*therapeutic use
MH  - Psychotic Disorders/*drug therapy/etiology/physiopathology
MH  - Risk Factors
MH  - Serotonin 5-HT2 Receptor Agonists/pharmacology/therapeutic use
MH  - Urea/*analogs & derivatives/pharmacology/therapeutic use
OTO - NOTNLM
OT  - Diagnostic criteria
OT  - Parkinson's disease psychosis (PDP)
OT  - progression
OT  - risk factors
OT  - symptoms
OT  - treatment
EDAT- 2019/06/05 06:00
MHDA- 2019/07/05 06:00
CRDT- 2019/06/05 06:00
PHST- 2019/06/05 06:00 [pubmed]
PHST- 2019/07/05 06:00 [medline]
PHST- 2019/06/05 06:00 [entrez]
AID - 10.1080/17512433.2019.1623669 [doi]
PST - ppublish
SO  - Expert Rev Clin Pharmacol. 2019 Jul;12(7):681-691. doi: 
      10.1080/17512433.2019.1623669. Epub 2019 Jun 13.